Company: TLSA
Filing Date: 2025-05-06
Form Type: 6-K
Source: 0001213900-25-039892
Chunk: 0

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-05-06
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9 thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F☒Form 40-F☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>

On May 6, 2025, Tiziana Life Sciences LTD (the “”)
issued this 6K announcing, promising results from an open-label clinical study evaluating nasal foralumab, the world’s only fully
human anti-CD3 monoclonal antibody administered intranasally, for the treatment of non-active secondary progressive multiple sclerosis
(na-SPMS). This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial
activation, and stabilized clinical progression in patients suffering from progression independent of relapse activity (PIRA)—a
major unmet need in the treatment of MS, and a key disease endpoint for intranasal foralumab development. The article is titled “Nasal
foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active
secondary progressive MS.” This study is the first to integrate, F18TSPO PET, Proteomics, and Clinical assessments in na-SPMS. These
findings in MFIS score reduction are a critically important Quality of Life (QoL) measure for patients with MS., a copy of which is furnished
as Exhibit 99.1

The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of